SCHEMBL2903152

SCHEMBL2903152

O=C(C=Cc1cccc(C(F)(F)F)c1)N1CCC(=O)N(CCCN2CCCCC2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.48
CCR2 P41597 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
ALDH1A1 P00352 1/20 0.45
TP53 P04637 1/20 0.45
HPGD P15428 1/20 0.45
KEAP1 Q14145 1/20 0.45
NFE2L2 Q16236 1/20 0.45
DRD2 P14416 2/20 0.43
DRD3 P35462 2/20 0.43
MAPT P10636 2/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
HSP90AA1 P07900 1/20 0.41
PKM P14618 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TRPV4 Q9HBA0 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MAPK1 P28482 1/20 0.40
HTR7 P34969 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2903149 1.00 LMNA (0.48) LMNACCR2SMN1; SMN2ALDH1A1TP53
SCHEMBL2896867 0.87 MEN1 (0.48) LMNAALDH1A1DRD2DRD3KMT2A
SCHEMBL2896871 0.87 MEN1 (0.48) LMNAALDH1A1DRD2DRD3KMT2A
SCHEMBL2896739 0.85 MEN1 (0.54) LMNASMN1; SMN2ALDH1A1HPGDMAPT
SCHEMBL2896736 0.85 MEN1 (0.54) LMNASMN1; SMN2ALDH1A1HPGDMAPT
SCHEMBL2904482 0.83 CCR2 (0.44) LMNACCR2ALDH1A1TP53MAPT
SCHEMBL2904480 0.83 CCR2 (0.44) LMNACCR2ALDH1A1TP53MAPT
SCHEMBL2905093 0.82 GPR183 (0.42) ALDH1A1DRD2DRD3MAPTKMT2A
SCHEMBL2905099 0.82 GPR183 (0.42) ALDH1A1DRD2DRD3MAPTKMT2A
SCHEMBL2899736 0.82 GPR183 (0.51) LMNASMN1; SMN2ALDH1A1TP53HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2010506-B1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS HOFFMANN LA ROCHE (CH) 2010-08-04 EP disclosed
US-7632829-B2 Diazepan derivatives HOFFMANN-LA ROCHE INC. (US) 2009-12-15 US disclosed
EP-2010506-A1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-Roche AG (CH) 2009-01-07 EP disclosed
WO-2007122103-A1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2007-11-01 WO disclosed
US-20070249589-A1 Novel diazepan derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249589-A1 Novel diazepan derivatives CCR3, CCR1, CCR10 LMNA 3307/4885CCR2 8/4885SMN1; SMN2 2573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.